ERBB2 and gastric cancer: In gastric cancer, targeted therapies have been developed and demonstrated to be effective for patients with human epidermal growth factor receptor 2 (HER2)‐positive,3 microsatellite instability (MSI)‐High,4 and neurotrophic tyrosine receptor kinase (NTRK) gene fusions.5